Due to the lower protection provided by EPIT, many individuals who complete EPIT go on to receive OIT. What is the difference between these individuals who have previously completed EPIT in comparison to those who initiate OIT without prior treatment? Wong et al investigated this question in an article published this February in Frontiers in Allergy by surveying 27 individuals who completed EPIT. Half the individuals who completed EPIT did not experience adverse events during the start of OIT, which is the period where adverse events are most common. Furthermore, 61% of these individuals did not experience any or rarely had adverse events in the later stages of OIT. However, not all participants who completed EPIT chose to receive OIT. Common reasons for not transitioning to OIT were OIT not being offered, choosing to withdraw from OIT after initiation (17% of those who transitioned), and fear of adverse events. Overall, these findings suggest that people who complete EPIT are less likely to have adverse reactions during OIT, however larger studies are needed to more closely examine the best way to implement this transition for interested individuals. For more information on the use of the transition from EPIT to OIT, see the full article HERE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939758/